Navigation Links
First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy

Researchers from Children's National Medical Center and colleagues in Tokyo publish results, video of first successful trial in dogs with Duchenne muscular dystrophy

Washington, DC (PRWEB) March 16, 2009 -- Genetic researchers at Children's National Medical Center and the National Center of Neurology and Psychiatry in Tokyo published the results of the first successful application of "multiple exon-skipping" to curb the devastating effects of Duchenne muscular dystrophy in an animal larger than a mouse. Multiple exon-skipping employs multiple DNA-like molecules as a "DNA band-aids" to skip over the parts of the mutated gene that block the effective creation of proteins.

The study, conducted in Japan and the United States, published this month in the peer-reviewed journal of the American Neurological Association, the Annals of Neurology, treated dogs with naturally occurring canine X-linked muscular dystrophy, a disease which is genetically homologous to the Duchenne muscular dystrophy that strikes 1 of every 3,500 boys born in the United States and worldwide each year.

Duchenne muscular dystrophy, one of the most common lethal genetic disorders, is an X-linked genetic mutation that causes an inability of the body's cells to effectively create dystrophin--which builds muscle tissue. "Exon-skipping" employs synthetic DNA-like molecules called antisense as a DNA band-aid to skip over the parts of the gene that block the effective creation of dystrophin. Because the gene's mutation could affect any of its 79 exons and sometimes more than one single exon at a time, scientists employed a "cocktail" of antisense called morpholinos to extend the range of this application. By skipping more than a single exon, this so-called DNA band-aid becomes applicable to between 80 and 90 percent of Duchenne muscular dystrophy patients, including the mutation found in dogs.

"This trial makes the much-talked about promise of exon-skipping as a systemic treatment for Duchenne muscular dystrophy in humans a real possibility in the near term," said Toshifumi Yokota, PhD, lead author of the study. "Of course this success has also introduced even more avenues for investigation, but these findings finally overcome a significant hurdle to our progress--we've solved the riddle of an effective system-wide delivery to muscle tissue, and seen promising results."

A new state-of-the-art facility at the National Center of Neurology and Psychiatry in Japan was utilized to carry out the research.

"This study delivers the proof-of-concept that systemic anti-sense therapy can be done in a large organism, in Duchenne muscular dystrophy or any disease", says Eric Hoffman, PhD, a senior author of the study and director of the Center for Genetic Medicine at Children's National Medical Center.

"Systemic treatment of the majority of Duchenne dystrophy will require multiple sequences to be delivered in the blood, and this study also is the first proof-of-principle of multiple exon-skipping in any organism," Shin'ichi Takeda, MD, another senior author, said. "In order to realize that promise in human trials, it also will be important to re-evaluate current measures of toxicity, efficacy, and marketing that ensure both safety for the patient, as well as rapid development and distribution of life-saving drugs.

The authors do note that significant steps still remain. Successful systemic treatment with morpholinos requires large doses of the antisense molecules--and the technology is costly and difficult to obtain. Additionally, treatment in this study showed diminished success at curbing muscle deterioration of the heart, meaning that a more effective and specific delivery system is needed to rescue the organ's delicate tissue in Duchenne muscular dystrophy patients. However, these early successes do show much promise for the oft-discussed exon-skipping method as an effective treatment for Duchenne muscular dystrophy and some other genetic disorders.

The post-treatment and non-treatment videos of the study are available on the Annals of Neurology website (

The study was funded by the Foundation to Eradicate Duchenne, the U.S. Department of Defense CDMRP Program, the Jain Foundation, the Crystal Ball Event of Hampton Roads and the Muscular Dystrophy Association USA, the National Center for Medical Rehabilitation Research, a collaborative grant from the U.S. National Institutes of Health Wellstone Muscular Dystrophy Research Centers, and several Grants-in-Aid from the Ministry of Health, Labour, and Welfare of Japan.


Children's National:
Jennifer Leischer/Emily Dammeyer

National Center of Neurology and Psychiatry of Tokyo:
Atsushi Sakuma/Shin'ichi Takeda

About Children's National Medical Center/Children's Research Institute
Children's National Medical Center, located in Washington, DC, is a proven leader in the development of innovative new treatments for childhood illness and injury. Children's has been serving the nation's children for more than 135 years. Children's National is proudly ranked among the best pediatric hospitals in America by US News & World Report and the Leapfrog Group. For more information, visit Children's Research Institute, the academic arm of Children's National Medical Center, encompasses the translational, clinical, and community research efforts of the institution. Learn more about our research programs at

About the National Center of Neurology and Psychiatry of Tokyo
The National Center of Neurology and Psychiatry (NCNP), located in Kodaira, Tokyo, has a mission to investigate the unknown causes of diseases, to establish treatment methods, and to develop a model of medical care. The Center also advances basic research. For more information, visit The National Institute of Neuroscience (NIN) is an institutional part of NCNP, established in 1986 to promote not only basic neuroscience but also clinical neuroscience based on a nationwide concept. The NIN is now composed of 7 basic sections divided by technology and 7 clinical sections divided by target neurological and psychiatric diseases. Learn more about our research programs at


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. First sister study results reinforce the importance of healthy living
2. Tampa Bay Becomes First Community to Jump-Start Americas E-Health Revolution
3. First treatment for muscular dystrophy in sight: Scientists successfully harness exon-skipping
4. Expresso Fitness(R) Launches First Virtual Reality Cardio Bike for Kids
5. ABMS Hosts First National Health Policy Forum to Address Physician Accountability and Health System Performance Standards
6. Young Onset Parkinson Conferences: A First-Ever Collaboration
7. First DHI-Licensed Door Inspection Software Solution Ships to DOORDATA Solutions' Charter Members
8. Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company
9. Beckman Coulter Announces First in Series of Flow Cytometry Product Introductions for 2009
10. First Rewards Paid to New Jersey Doctors Through Participation in Bridges to Excellence
11. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
Post Your Comments:
Related Image:
First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy 
(Date:12/1/2015)... ... 2015 , ... CloudLIMS today announced that it is the ... the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's SaaS ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... must mark the film for accurate interpretation by the radiologist. The marking utensils ... inventor from Sacramento, Calif., has found a way to alleviate this problem. , ...
(Date:12/1/2015)... ... 2015 , ... McLean, VA., December 1, 2015 - Octo ... sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services ... engineering, infrastructure, as well as operations and sustainment support to the NGA’s Agile ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as ... Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center marketplace. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a country ... drugs registered in Europe in 2015 were tested ... Russia has always been a country of choice ...
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: